<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HCD1AAE88552847C598669A13874CB6E5" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 2557 IH: Prostate Cancer Misdiagnosis Elimination Act of 2017</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2017-05-19</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 2557</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20170519">May 19, 2017</action-date><action-desc><sponsor name-id="B001275">Mr. Bucshon</sponsor> (for himself, <cosponsor name-id="P000604">Mr. Payne</cosponsor>, <cosponsor name-id="C001072">Mr. Carson of Indiana</cosponsor>, <cosponsor name-id="M001190">Mr. Mullin</cosponsor>, and <cosponsor name-id="R000515">Mr. Rush</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend title XVIII of the Social Security Act to provide for coverage under the Medicare program
			 of certain DNA Specimen Provenance Assay clinical diagnostic laboratory
			 tests.</official-title></form>
	<legis-body id="HD2BB9E9360BD474089B79967EEDB9A8A" style="OLC">
 <section id="HA821FC814D5847E798B660E31B9C0404" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Prostate Cancer Misdiagnosis Elimination Act of 2017</short-title></quote>.</text> </section><section id="H90840709D8054C428B8D19AB3294437B"><enum>2.</enum><header>Coverage of certain DNA Specimen Provenance Assay clinical diagnostic laboratory tests under Medicare</header> <subsection id="H9E00AB6056E34AE1B7703826F9B07E48"><enum>(a)</enum><header>Coverage</header><text display-inline="yes-display-inline">Section 1862(a)(1) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395y">42 U.S.C. 1395y(a)(1)</external-xref>) is amended—</text>
 <paragraph id="HAE08792F442E42ED9F9F9A5F53552E11"><enum>(1)</enum><text>in subparagraph (O), by striking <quote>and</quote> at the end;</text> </paragraph><paragraph id="H679C55B98F46408E81BE4D29BD90FF64"><enum>(2)</enum><text>in subparagraph (P), by striking the semicolon at the end and inserting <quote>, and</quote>; and</text>
 </paragraph><paragraph id="HB2F89293101F405699558E359CAF9C1B"><enum>(3)</enum><text>by adding at the end the following new subparagraph:</text> <quoted-block display-inline="no-display-inline" id="HD7E668B1CF0A4E689C05FD6D83248171" style="OLC"> <subparagraph id="H28B758D87AEA4A418A7A55F759D20241" indent="up1"><enum>(Q)</enum><text display-inline="yes-display-inline">in the case of a DNA Specimen Provenance Assay clinical diagnostic laboratory test (DSPA test), unless the DSPA test is furnished to an individual enrolled under part B who has had a prostate cancer biopsy the results of which are positive, the DSPA test is furnished with respect to such biopsy, and the DSPA test is ordered by the physician who furnished the prostate cancer biopsy that obtained the specimen tested;</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph></subsection><subsection id="H6CE37B3E1C7149CB8C87F9DDC3131C74"><enum>(b)</enum><header>Temporary payment amount for tests furnished during 2018 through 2020 and related requirements</header><text>Section 1834A of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395m-1">42 U.S.C. 1395m–1</external-xref>) is amended—</text> <paragraph id="H54C15F5784B94439B6919DC51F866386"><enum>(1)</enum><text>in subsection (b)(1)(A), by striking <quote>and (d)</quote> and inserting <quote>, (d), and (j)</quote>; and</text>
 </paragraph><paragraph id="H353A7647F51C4D41A2449952F2086D31"><enum>(2)</enum><text>by adding at the end the following new subsection:</text> <quoted-block display-inline="no-display-inline" id="HB67C54B5E9F6481F9B24DC4B09489CD3" style="OLC"> <subsection id="H970BC1704F0A4CF5B7E2A486C9985D76"><enum>(j)</enum><header>DNA Specimen Provenance Assay clinical diagnostic laboratory tests</header> <paragraph id="H114FC1266CB1454CB7680A48C8D4D482"><enum>(1)</enum><header>Temporary payment amount for tests furnished during 2018 through 2020</header><text>Notwithstanding the payment amount that would otherwise apply under this section, with respect to a DNA Specimen Provenance Assay clinical diagnostic laboratory test furnished on or after January 1, 2018, and before January 1, 2021, the payment amount under this section shall be equal to 85 percent of the amount determined under the fee schedule under section 1833(h)(1) for 2016 for HCPCS code 81265.</text>
 </paragraph><paragraph id="H7CE7BECB0E6E4ECCA320D5FED2ED4911"><enum>(2)</enum><header>HCPCS code assignment</header><text>The Secretary shall assign an HCPCS code to the DNA Specimen Provenance Assay clinical diagnostic laboratory test.</text>
							</paragraph><paragraph id="H5BBD083AAE6742B99247A0A069C236B8"><enum>(3)</enum><header>Ensuring proper billing and payment</header>
 <subparagraph id="H5CA6A7DC59E24AD490EFBBBE39FD5AA0"><enum>(A)</enum><header>Use of modifier to ensure proper payment</header><text>The Secretary may use a modifier to facilitate making payment under this section with respect to a DNA Specimen Provenance Assay clinical diagnostic laboratory test.</text>
								</subparagraph><subparagraph commented="no" id="H95CE43799E1647409865A9788D04C814"><enum>(B)</enum><header>Paid claims sample error rate</header>
 <clause commented="no" id="HFC1D2E86A16F4CF9ACDC01E6E285E4C4"><enum>(i)</enum><header>In general</header><text>The Secretary shall conduct a post-payment review of a sample of not less than 50 claims for DNA Specimen Provenance Assay clinical diagnostic laboratory tests for which payment is made under this part. The sample reviewed under the preceding sentence may be taken from claims paid to more than one supplier.</text>
 </clause><clause commented="no" id="H47EAB52D5E2C4D2895CA289BBCABDA5B"><enum>(ii)</enum><header>Posting on Internet website</header><text>Not later than July 1, 2019, the Secretary shall post on the Internet website of the Centers for Medicare &amp; Medicaid Services the number of claims with errors identified based on the reviews conducted under clause (i).</text></clause></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="H4181135279F142ADBD28A6F12CDABA82"><enum>(c)</enum><header>Effective date</header><text>The amendments made by this section shall apply to DNA Specimen Provenance Assay clinical diagnostic laboratory tests furnished on or after January 1, 2018.</text>
			</subsection></section></legis-body></bill>


